Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 226

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 226
---
 by which the Company must consummate a business combination from March 9, 2024 to June 9, 2024 (subject to an additional three month extension at the discretion of the Iris Board). The Company’s stockholders approved the amendment to the Iris Certificate of Incorporation at the special meeting on March 7, 2024. On March 9, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date from March 9, 2024 to July 31, 2024.

<div align='center'>103</div>

TABLE OF CONTENTS

On May 13, 2024, the Iris Board extended the date by which the Company must consummate a Business Combination for a three month period from June 9, 2024 to September 9, 2024, pursuant to the discretion granted to the Iris Board by the stockholders.

On July 19, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date from July 31, 2024 to September 3, 2024.

On August 16, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to extend the Outside Date to December 31, 2024. Also on August 16, 2024, the parties to the Subscription Agreement entered into an amendment to such agreement to extend the termination date of the agreement to December 31, 2024.

On August 26, 2024, the Company filed a proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to extend the date by which the Company must consummate a business combination from September 9, 2024 to December 31, 2024. The Company’s stockholders approved the amendments to the Iris Certificate of Incorporation at the special meeting on September 5, 2024. On September 5, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to its amended and restated certificate of incorporation to change the date by which the Company must consummate a business combination to December 31, 2024.

On October 23, 2024, the parties to the Business Combination Agreement amended the Business Combination Agreement to, among other things, reduce the enterprise value associated with Liminatus to $175 million. On October 31, 2024, the parties to the Subscription Agreement entered into an